Drugs / XP-005
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06980155 | May 2025 → Jan 2027 expected | acute myeloid leukemia | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP-005 | “XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia” NCT06980155 ↗ |
| Modality | Messenger RNA (mRNA) | “XP-005 personalized tumor mRNA vaccine” NCT06980155 ↗ |